Expression and functions of galectin-7 in ovarian cancer

Marilyne Labrie; Maria Claudia Vladoiu; Andrée-Anne Grosset; Louis Gaboury; Yves St-Pierre

doi:10.18632/oncotarget.2299

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Expression and functions of galectin-7 in ovarian cancer

Marilyne Labrie, Maria Claudia Vladoiu, Andrée-Anne Grosset, Louis Gaboury and Yves St-Pierre _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2014; 5:7705-7721. https://doi.org/10.18632/oncotarget.2299

Metrics: PDF 2144 views | HTML 3269 views | ?

Abstract

Marilyne Labrie1, Maria Claudia Vladoiu1, Andrée-Anne Grosset1, Louis Gaboury2 and Yves St-Pierre1

1 INRS-Institut Armand-Frappier, Laval, Québec, Canada

2 Institute for Research in Immunology and Cancer, Downtown Station, Montréal, Québec, Canada

Correspondence:

Yves St-Pierre, email:

Keywords: galectin-7, ovarian cancer, immunosupression, p53, MMP-9

Received: June 09, 2014 Accepted: July 31, 2014 Published: July 31, 2014

Abstract

There is a critical need to develop effective new strategies for diagnosis and treatment of ovarian cancer. In the present work, we investigated the expression of galectin-7 (gal-7) in epithelial ovarian cancer (EOC) cells and studied its functional relevance. Immunohistochemical analysis of gal-7 expression in tissue microarrays showed that while gal-7 was not detected in normal ovarian tissues, positive cytoplasmic staining of gal-7 was detected in epithelial cells in all EOC histological subtypes but was more frequent in high grade tumors and metastatic samples. Gal-7 expression correlated with a significant difference in the overall survival of patients with ovarian serous cystadenocarcinoma. Furthermore, using human EOC cell lines, we found that gal-7 expression was induced by mutant p53. Mechanistically, Matrigel invasion assays and live cell imaging showed that gal-7 increased the invasive behavior of ovarian cancer cells by inducing MMP-9 and increasing cell motility. EOC cells can also secrete gal-7. Recombinant human gal-7 kills Jurkat T cells and human peripheral T cells, suggesting that gal-7 also has immunosuppressive properties. Taken together, our study validates the clinical significance of gal-7 overexpression in ovarian cancer and provides a rationale for targeting gal-7 to improve the outcome of patients with this disease.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2299

Publication Alerts

Research Papers:

Expression and functions of galectin-7 in ovarian cancer

Abstract